β-Thalassemia is a genetic disorder caused by defects in the β-globin gene resulting in the absence or reduced synthesis of adult hemoglobin (HbA). Hydroxyurea is an effective drug to increase fetal γ-globin (HbF) expression, replacing the missing adult β-globin. The mechanism of HbF induction by hydroxyurea and improvement in clinical symptoms are still poorly understood. In the present study we performed comparative analysis of plasma proteome in pre-and post-hydroxyurea-treated β-thalassemia major transfusion-dependent children (n = 10, mean age = 3.2 years) as well as responders versus nonresponders to hydroxyurea treatment. Plasma was collected before and after 6 months of hydroxyurea treatment, with patients subcategorized on the basis of their response to hydroxyurea. Among 400 identified proteins using a label-free quantitative proteomics approach, 28 proteins were found to be significantly different in pre-versus post-hydroxyurea-treated groups, with transferrin receptor protein-1 being most downregulated and hemopexin and haptoglobin the most upregulated proteins after treatment. In responder versus nonresponder comparison, 26 proteins were found to be differentially expressed, with carbonic anhydrase 1, hemoglobin subunit γ-1, and peroxiredoxin-2 showing the significant changes. The mechanism of hydroxyurea treatment in β-thalassemia patients appears to be complex, requiring a large sample size and a longer period of treatment to reveal its details.
Thalassemias are among the most prevalent autosomal recessive monogenic disorders. It is estimated that 5.2% of the world population are carriers of hemoglobin (Hb) disorders, including α-or β-thalassemia. The annual increment is 330 000 affected new births, mostly in the developing world.
1 β-Thalassemia major, the catastrophic form of thalassemia, is predominant in the tropical and subtropical regions of the Mediterranean, Middle East, Indian subcontinent, Southeast Asia, and Southern China. 2 Induced production of the γ -globin chains reduces α/β-chain imbalance in β-thalassemia through the formation of fetal Hb (HbF), thereby increasing effective erythropoiesis and reducing hemolysis and the level of anemia. 3 Observed clinical benefits of HbF motivated researchers to explore therapeutic agents capable of HbF induction. Decitabine and 5-azacytidine, as DNA-hypomethylating agents, sodium butyrate as an inhibitor of histone deacetylase, and hydroxyurea as a cytotoxic agent are proven HbF inducers because they augment γ -globin expression. 4 Hydroxyurea is an FDA-approved antimetabolite for the treatment of sickle cell disease (SCD). 5 HbF induction in SCD occurs by inhibition of sickle cell Hb (HbS) through anticipated key genomic variants such as BCL11A, HBS1L-MYB, or SAR1. The same variants may also contribute in clinical manifestation by specific signal transduction pathways including cAMP/cGMP, Gia/c-Jun N-terminal kinase/Jun, methylation, and microRNA, which regulate γ -globin expression. However, the comprehensive delineation of hydroxyurea-mediated HbF production remains vague in SCD. 6 Currently, β-thalassemia patients are also widely treated with hydroxyurea for HbF augmentation with variable responses, from transfusion independence to null outcome. Studies on the use of hydroxyurea in β-thalassemia patients have suggested some clinical benefits of hydroxyurea with better growth, improved life quality, and increased overall survival. [7] [8] [9] Despite the beneficial effects of hydroxyurea, however, its mechanism of action in β-thalassemia remains a question to be answered. In recent years the expanding realm of clinical proteomics has added a unique dimension to the study of pathophysiology by analyzing differential protein expression levels associated with specific disorders, eg, Alzheimer disease. 10 Proteomics offers potentially colossal benefits by analyzing the drug-induced protein expression response, which in turn may reveal the underlying targets and mechanisms of action. 11 Here, we pragmatically applied a label-free quantitative proteomic approach to identify and quantify changes in plasma protein expression that were reflected in the hydroxyurea-treated β-thalassemia patients. 12 The current study also strengthens the notion that exploration of plasma proteomics improves the molecular understanding of drug-induced alterations and reveals proteins or their modifications that are related to responsiveness of hydroxyurea treatment in β-thalassemia.
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Materials and Methods
Patient Selection and Sample Collection
The present study was conducted according to ethical guidelines as outlined in World Medical Association Declaration of Helsinki after approval of an institutional review board (NCP-IRB-111). Written informed consent was obtained from the legal guardians of studied patients. In the current study we considered 10 β-thalassemia major transfusion-dependent patients with definite diagnosis based on genetic analysis. Patients with evidence of any other chronic illness unrelated to β-thalassemia or having any allergic reaction to hydroxyurea were excluded from the study. Samples were collected from recruited β-thalassemia patients before the treatment, and a second sample was collected following 6 months of treatment with hydroxyurea at a dose of 15 mg/kg. Treated patients were further categorized into 2 groups on the basis of their response to hydroxyurea. Patients denoted as responders (n = 5) achieved a ࣙ50% increment in transfusion interval, whereas those showing a <50% reduction in transfusion requirement are referred as nonresponders (n = 5). About 3 mL of peripheral blood was collected from each patient in a K 2 EDTA spray-coated vacutainer (BD, Franklin Lakes, New Jersey) before transfusion. Plasma was separated by centrifugation at 2500g for 15 minutes at 4°C and immediately stored at −80°C until further analysis. 
In-Solution Trypsin Digestion
NanoLC-MS/MS Analysis
For each run, a quantity of 7 μL (equivalent to 1.4 μg) of digested proteins was injected into a reversed-phase liquid chromatography (LC) system EASY-nLC TM II nano-LC (ThermoFisher Scientific) equipped with NanoViper 75 μm id × 50 cm Acclaim PepMap RSLC C18 column (ThermoFisher Scientific) with particle size of 2 μm and pore size of 100Å. A constant flow rate of 300 nL/min was maintained during elution of peptides. Buffers A and B contained 2% acetonitrile/0.1% formic acid and 98% acetonitrile/0.1% formic acid, respectively. The chromatographic separation was achieved by applying a linear gradient of buffer B from 2% to 26% for 90 minutes, with subsequent gradient increase to 95% buffer B in 5 minutes. This was held for 8 minutes, and thereafter the column was reequilibrated for 10 minutes by returning the gradient to 2% buffer B. Data-dependent acquisition was set on a Q-Exactive Orbitrap Plus mass spectrometer (ThermoFisher Scientific) using positive ion mode electrospray ionization. Resolution was set to 40,000 for "survey" mass spectra and to 17,500 for MS/MS spectra with an m/z range of 300 to 1650. The mass spectrometric (MS) Automatic Gain Control (AGC) target was 5 × 10 6 , whereas the AGC target for MS/MS was 2 × 10 5 . The isolation window width was 4 m/z units with 90 seconds of dynamic exclusion.
Label-Free Relative Quantitative Analysis of Proteomic Data LC-MS raw files were quantitatively analyzed by MaxQuant software version 1.5.6.5 14, 15 (Max Planck Institute of Biochemistry) using the complete proteome set of humans (UP000005640 9606 Homo sapiens) which contains 21,042 entries. Cysteine carbamidomethylation as a fixed modification with Nterminal acetylation and methionine oxidation as variable modifications were running parameters, together with trypsin as digestion enzyme, permitting a maximum of 2 missed cleavages. False discovery rates for identification of both peptides and proteins were set at 1%. Plasma samples were compared in terms of the label-free quantification intensities.
Label-free quantitative data were statistically evaluated by Perseus (Version 1.6.0.7, Max Planck Institute of Biochemistry). Data filtration was done to remove proteins "only identified by sites," identified by reversed sequences and potential contaminants. Comparison of the hydroxyurea-treated and hydroxyureauntreated samples, as well as responders versus nonresponders analysis were performed. Average labelfree quantitative intensities and standard deviation with fold change in protein levels were calculated for all groups. A paired t-test was applied to compare 2 groups, and relationships between variables were assessed by application of the Pearson correlation coefficient. Any protein identified with a minimum of 2 peptides, minimum fold change of ±1.5, and P-value < .05 was considered to be significantly differentially expressed. For protein-protein interaction analysis, accession numbers of differentially expressed proteins were uploaded into the STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database (STRING Consortium 2018) selecting multipleproteins search as a choice. 16 The database was searched against identified proteins in groups, pre-versus posttreatment and responder versus nonresponder except immunoglobulins.
Results
Clinical details of the studied population including hematological parameters and thalassemia genetics are shown in Table 1 . First, plasma proteomic profiles of 10 β-thalassemia patients (5 male and 5 female) with a mean age of 3.2 years were analyzed on the basis of preand post-hydroxyurea treatment of 6 months' duration. Second, proteomics comparison was performed on the basis of therapeutic response of hydroxyurea as suggested by the reduction in transfusion requirement. In pre-versus posttreatment groups, correlation analysis revealed a high degree of repeatability in biological and technical replicates indicated by Pearson coefficients in the ranges of 0.83-0.98 and 0.85-0.99, respectively. Similarly, a high degree of repeatability was observed in the response group with Pearson coefficients of 0.82-0.97 and 0.89-0.99 in biological and technical replicates, respectively. A total of 400 and 287 proteins were identified and quantified by MaxQuant software with a minimum of 1 and 2 unique peptides, respectively. Of the latter, 28 proteins had P <.05 (paired t test) with a threshold fold change >1.5 in post-versus pretreatment comparison, with 18 proteins being downregulated and 10 upregulated (Table 2) . Transferrin receptor protein-1 was the most downregulated, and hemopexin and haptoglobin were the most upregulated proteins. A total of 26 proteins were differentially expressed in responders versus nonresponders in the treated cohort; among these, 15 proteins showed a level increase, and 11 proteins exhibited a decrease (Table 3) . Carbonic anhydrase 1, Hb subunit γ -1, and peroxiredoxin-2 were the 3 most upregulated proteins. Analysis of protein-protein interaction using STRING in the pre-and post-hydroxyurea treatment groups was conducted using TFRC, ORM1, LPA, LRG1, ORM2, ITIH3, AMBP, CP, SERPINA1, APCS, APOC1, APOL1, HPR, HBA1, HBD, HBB, HP, HPX, C4A, FCN3, F10, and S100A8 as input. Most of the differentially expressed proteins were found to be linked with each other except for a few ( Figure 1A) . Similar to the pre-and post-Htreatment groups, functional protein association and network analysis were performed for proteins showing significant difference in expression among responders and nonresponders to the hydroxyurea plasma proteome. Two different protein-linking networks were observed, 1 connecting HBA1, HBD, HB, HGB1, and CA1 and the other showing relations among FGB, LGALS3BP, SERPING1, ORM2, and F1. The remaining proteins did not show any connections with other proteins and spread out separately ( Figure 1B ).
Discussion
Induced HbF production by hydroxyurea is the appealing therapeutic approach to ameliorate the severity of β-thalassemia. 7, 9 However, variable response to the drug presents various limitations. Earlier studies on pharmacogenomics mainly dealt with identification of genomic variants in γ -globin, BCL11A, and HBS1L-MYB, which might be responsible for the selective response to hydroxyurea treatment. 17, 18 Because so far there is no genomic biomarker on the basis of which hydroxyurea therapy can be adapted for SCD and β-thalassemia patients, [19] [20] [21] we decided to take a pharmacoproteomics approach. In the past decade rapid technical developments in tandem MS and label-free quantification have resulted in meaningful understanding of pathological pathways, biomarkers, and drug mechanisms at the proteome level. 22 Therefore, identification of differentially expressed proteins in response to hydroxyurea treatment is likely to complement existing knowledge about drug mechanism along with providing additional information regarding therapeutic response. Various approaches are used to understand the mechanisms of γ -globin upregulation and differential response. Previous in vivo and in vitro studies have investigated the effect of hydroxyurea in the sickle red blood cell membrane proteome. 23, 24 In the current study, a label-free quantification approach was employed that resulted in the identification of 287 proteins with 2 or more unique peptides. A strong correlation between biological and technical replicates was observed that showed a high level of sample-tosample and run-to-run repeatability, thus validating the current analysis.
We found 28 proteins to be differentially expressed in a post-versus pretreatment comparison. An interesting observation is the downregulation of transferrin receptor protein-1 and the upregulation of hemopexin, haptoglobin, and haptoglobin-related protein. Soluble transferrin receptor protein-1 plays a central role in the pathophysiology of β-thalassemia because of its involvement in iron transportation to the cells. Because of hemolysis and ineffective erythropoiesis in β-thalassemia, elevated levels of soluble transferrin receptor protein-1 have been reported. 25 Although there are some reports suggesting effects of hydroxyurea therapy on transferrin receptor protein-1 levels in sickle cell/β-thalassemia 26 and HbE/β-thalassemia, 27 data regarding β-thalassemia are not available. The current study showed a 4-fold reduction in the transferrin receptor protein-1 level in hydroxyurea-treated plasma, suggesting a decrease in erythropoietic stress and an increase in effective erythropoiesis. These processes are also reflected in the clinical outcome of hydroxyurea therapy (Table 1) . Hemopexin, haptoglobin, and haptoglobin-related protein are circulating Hb scavenger proteins with their known role in the pathology of hemolytic diseases. Decreased plasma hemopexin values imply a severe degree of hemolysis, mainly observed in thalassemia major and sickle cell anemia. 28 Rapid haptoglobin depletion in individuals with increased free Hb results in decreased plasma haptoglobin levels, making these decreased levels a highly sensitive and specific hemolysis indicator. 29 Haptoglobin levels in plasma from β-thalassemia subjects provide a reliable marker of red cell destruction and are correlated with severity of disease as the degree of decline is greater in β-thalassemia major than in β-thalassemia intermedia. 30 Our study showed increases in hemopexin, haptoglobin, and haptoglobin-related protein in hydroxyurea-treated plasma of β-thalassemia, thus confirming the clinical benefits of hydroxyurea in the form of reduced hemolysis and enhanced erythropoietic activity. It is worth mentioning that the transferrin receptor protein-1 level is inversely proportional to hemopexin and haptoglobin levels, suggesting that either protein, or their ratio, can be used to assess the therapeutic benefits of hydroxyurea. Furthermore, levels of ApoL1, a minor apoprotein component of highdensity lipoprotein, also showed a 1.4-fold increase in posttreated hydroxyurea patients. ApoL1 is involved in cell-free Hb scavenging through association with haptoglobin-related protein. 31 Higher expression of ApoL1 along with upregulation of haptoglobin and haptoglobin-related protein in posttreated samples reflects their coordinated role in the reduction of hemolysis and enhanced erythropoietic activity. Another protein found to be overexpressed in response to treatment is S100-A8, which is involved in p38-dependent phosphorylation. 32 hydroxyurea also triggers the same pathway and activates γ -globin via a p38-dependent mechanism, 33, 34 thus justifying upregulation of S100A8.
Among the 26 proteins found differentially expressed in responders versus nonresponders in the treated cohort, the most significant difference was Hb subunit γ -1, carbonic anhydrase 1, and peroxiredoxin-2. The Hb subunit γ -1 was observed to be significantly higher in a responder group along with upregulated expression of α-, β-, and δ-globin chains. Although hydroxyurea is known for stimulating γ -globin production, it may have a broader role in augmenting globin synthesis including β-globin production and, directly or indirectly, α-globin products. 35 It has been argued that there is a simultaneous increase of γ -and β-globins that is compensated for by a concomitant increase of α-globin, which is reflected by an increase in total Hb level and reduction in transfusion frequency. Similarly, δ-globin induction might be clinically important, comparable to HbF. 36 Because the pharmacological augmentation of HbF by increasing γ -globin can correct the globin chain imbalance in β-thalassemia patients while inhibiting HbS polymerization in SCD patients, 37 it can be hypothesized that an increase in δ-globin might play a similar protective role in β-thalassemia, as observed in our study. Indeed, δ-globin levels are higher at younger ages, which is depicted by increased HbA 2 levels 38 ; however, our data also indicate increased δ-globins in posttreated as well as in the responder cohort due to the effect of hydroxyurea therapy in β-thalassemia patients.
Peroxiredoxin-2 is a member of the peroxiredoxin antioxidant enzyme family with a conserved cysteine residue that scavenges peroxides and reduces their level, thus playing a cytoprotective role. 39 Increased expression of peroxiredoxin-2 has been reported in erythrocytes, 40 erythroid precursor cells, 41 and platelets 42 derived from β-thalassemia/HbE patients. In another study, peroxiredoxin-2 has been found to target both reactive oxygen species and heme to reduce oxidative stress in β-thalassemia erythroid precursors, which suggests a possible multifunctional cytoprotective role. 43 In a pharmacoproteomic study of hydroxyurea in sickle cells, increased expression of peroxiredoxin-2 in the red cell membrane proteome has also been revealed. 23 Label-free quantitative analysis in the present study has showed that plasma concentration of peroxiredoxin-2 increased in responders. This observation is not surprising because peroxiredoxin-2 is involved in a cytoprotective mechanism in β-thalassemia. The other most significantly upregulated protein, carbonic anhydrase-1, is a family member of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide to bicarbonate and hydrogen ion and contribute to multiple biological processes. The expression level of carbonic anhydrase-1 has been shown to be increased in erythroid precursor cells, 41 erythrocytes, 40 and platelets 42 derived from β-thalassemia/HbE patients. Similar to peroxiredoxin-2, carbonic anhydrase-1 was also increased in hydroxyurea-treated sickle red cell membrane proteome. 23 Notably, carbonic anhydrase-1 level in our study was also 7 times higher in the responder as compared to the nonresponder subgroup. Furthermore, carbonic anhydrase-1 is an early specific marker of erythroid differentiation, and its expression is closely associated with the shift from fetal to adult Hb production in erythroid cells through the Ldb1 protein complex. 44 This information provides further support for the likelihood that carbonic anhydrase-1 is involved in the mechanism of responsiveness to hydroxyurea.
To the best of our knowledge, the current study represents the first attempt to assess the effects of hydroxyurea on the plasma protein profile in β-thalassemia patients. Small sample size, short duration of the treatment with hydroxyurea, and the absence of a protease inhibitor cocktail in plasma samples are the limitations of the current study. Despite these limitations, we identified several differentially expressed proteins, some of which have previously been reported as contributors to the pathophysiology of different hemoglobinopathies other than β-thalassemia. In addition to the proteins discussed above, we also identified other differential plasma proteins, as shown in Tables 2 and 3 . However, their relationship with thalassemia or hydroxyurea has not yet been deciphered. The involvement of various proteins and different biological pathways suggests that the mechanism of hydroxyurea in β-thalassemia is complex, and a larger sample size study with a longer period of treatment with hydroxyurea is needed to gain deeper insight into the precise mechanism.
